HELX vs LFSC
Franklin Genomic Advancements ETF against F/m Emerald Life Sciences Innovation ETF: cost, size, returns, what they hold and how much of it is the same.
Overlap by weight
16%
9 shared positions
Fee gap
4 bp
HELX is cheaper
1-year return gap
11.9 pts
LFSC is ahead
Larger fund
LFSC
$118M
Side by side
| HELX | LFSC | |
|---|---|---|
| Fund | Franklin Genomic Advancements ETF | F/m Emerald Life Sciences Innovation ETF |
| Issuer | Franklin Templeton | F/m Investments |
| Category | Biotech & Health Innovation | Biotech & Health Innovation |
| Expense ratio | 0.50% | 0.54% |
| Assets | $32M | $118M |
| Average daily dollar volume | $441K | $111K |
| Listed | Feb 25, 2020 | Oct 30, 2024 |
| FrenzyCap score | 42 | 36 |
| 1-month return | +3.9% | −6.1% |
| 3-month return | +7.3% | −5.7% |
| Year to date | +17.4% | +16.4% |
| 1-year return | +29.2% | +41.1% |
| 30-day volatility | 28.2% | 23.2% |
| Worst drawdown, 1 year | −18.0% | −16.3% |
| Trailing 12-month yield | 0.34% | — |
| Holdings | 63 | 40 |
| Top 10 weight | 47.1% | 54.7% |
| Look-through P/E | 64596.3 | — |
| Holdings vs fair value | −3.0% | −4.0% |
| Holdings above 200-day average | 73% | 55% |
| Net flow, latest 3 reported months | +$2.0M thru Jun 2026 | +$1.2M thru May 2026 |
| 30-day implied volatility | 37.1% | — |
| Holdings as of | as of Jun 30, 2026SEC filing | as of May 31, 2026SEC filing |
Returns are price returns and exclude distributions. Flows are each fund's own latest reported months and may not cover the same period.
Largest shared holdings
26% of HELX · 25% of LFSC
Sector mix of the stock holdings
| Sector | HELX | LFSC | Gap |
|---|---|---|---|
| Health Care | 80.2% | 88.3% | −8.1% |
| Technology | 5.8% | 2.2% | +3.6% |
| Consumer Staples | 2.3% | 0.0% | +2.3% |
| Industrials | 0.0% | 0.4% | −0.4% |
More: full overlap table · HELX holdings · LFSC holdings
Fund data comes from each fund's SEC filings and issuer disclosures and is shown with the date it is as of. SEC portfolio and flow filings become public about 60 days after the period they cover. Nothing here is investment advice; see Terms.